Article

FDA Approves Jentadueto for Type 2 Diabetes

Author(s):

The US Food and Drug Administration has approved Jentadueto, a type 2 diabetes treatment that combines two drugs (linagliptin and metformin) in a single pill.

The US Food and Drug Administration (FDA) has approved Jentadueto, a type 2 diabetes treatment that combines two drugs (linagliptin and metformin) in a single pill.

From Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly, Jentadueto is a twice-daily prescription tablet designed for use in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes.

The drug’s approval is based on the results of a 24-week, randomized, double-blind, placebo-controlled study that assessed the safety and efficiency of linagliptin plus metformin when used with diet and exercise in 791 adults with type 2 diabetes.

They study found that 2.5 mg linagliptin in combination with 1,000 mg metformin twice daily resulted in a reduction of HbA1c levels of up to 1.7%.

While it is not yet known whether Jentadueto is safe and effective when used with insulin, many are excited about the approval.

"Most people with type 2 diabetes require more than one medication to help lower their blood sugar, due to the complex nature of type 2 diabetes," said Lance Sloan, MD, of the Texas Institute for Kidney and Endocrine Disorders, in a press release from the two companies.

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
© 2024 MJH Life Sciences

All rights reserved.